Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study.

in The Lancet. Oncology by Achal Neupane, Qi Liu, Siddhant Taneja, Jennifer French, Matthew J Ehrhardt, Tara M Brinkman, Rachel Webster, Jun J Yang, Cindy Im, Lucie M Turcotte, Joseph P Neglia, M Monica Gramatges, Rebecca M Howell, Smita Bhatia, Kirsten K Ness, Melissa M Hudson, Gregory T Armstrong, Leslie L Robison, Yutaka Yasui, Yadav Sapkota

TLDR

  • The study found that radiotherapy and genetic predisposition are primary contributors to the risk of subsequent neoplasms in childhood cancer survivors.
  • The study highlights the need for individualized risk assessment and tailored surveillance strategies for childhood cancer survivors.

Abstract

Survivors of childhood cancer are at risk of subsequent neoplasms (SNs) associated with exposure to radiotherapy and chemotherapy, as well as with genetic predisposition. We aimed to estimate the relative contributions of these risk factors to the total SN burden in survivor populations. We analysed data from two retrospectively constructed cohorts with ongoing recruitment and prospective follow-up: the St Jude Lifetime Cohort (SJLIFE; 4401 participants; NCT00760656) and the Childhood Cancer Survivor Study (CCSS; 7943 participants; NCT01120353). We used multivariable piecewise-exponential models to calculate attributable fractions to assess the contributions of radiotherapy and chemotherapy exposures, genetic predisposition (comparing the top two tertiles with the lowest tertile of polygenic risk scores [PRSs] where the tertile is from external general population corresponding to SN outcome) and lifestyle factors (physical activity, smoking, alcohol consumption, obesity, and diet) to incident of the first occurrences of SNs as the primary outcome. The study was conducted between Jan 1, 2024, and Sept 30, 2024. Of the 12 344 survivors eligible for analysis, median attained age was 33·0 years (IQR 24·1-42·1) in SJLIFE and 36·0 years (29·5-43·6) in CCSS; 6127 (49·6%) were men and 6217 (50·4%) were women. Most patients were White (10 907 [88·4%]). The median follow-up from primary cancer diagnosis was 24·2 years (IQR 11·7-35·4) in SJLIFE (from Sept 13, 2007 to April 20, 2020) and 28·0 years (8·9-37·2) in CCSS (from Jan 1, 1975 to Dec 31, 2023). Cancer treatments and genetic risk jointly contributed to a substantial proportion of incident SN cases with attributable fractions ranging from 30% (95% CI 6-49; sarcoma) to 92% (89-94; meningioma). Higher exposure levels of radiotherapy contributed most, particularly in older (≥35 years; SJLIFE proportion of SNs 44·7% [95% CI 41·9-47·5]) compared with younger (<35 years; 40·0% [37·1-43·3]) follow-up age periods. Elevated genetic risk based on the PRSs accounted for a notable proportion, ranging from 1% (95% CI 0-7; meningioma) to 52% (39-62; thyroid cancer), surpassing contributions of chemotherapies, ranging from 3% (1-6; SMNs) to 35% (19-49; sarcoma). Lifestyle factors contributed negligibly. Cancer treatments and genetic predisposition are primary contributors to the risk of SNs in childhood cancer survivors, and lifestyle factors seem to have a minimal effect. These results highlight the crucial need to consider both treatment history and genetic factors in developing effective risk assessment and surveillance strategies for this vulnerable population. US National Institutes of Health and the American Lebanese Syrian Associated Charities.

Overview

  • The study aimed to estimate the relative contributions of radiotherapy, chemotherapy, and genetic predisposition to the burden of subsequent neoplasms in childhood cancer survivors.
  • The study analyzed data from two cohorts: the St Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS), totaling 12,344 survivors.
  • The study found that cancer treatments and genetic factors jointly contributed to a substantial proportion of incident SN cases, with radiotherapy exposure being a primary contributor.

Comparative Analysis & Findings

  • The study found that radiotherapy exposure accounted for 30-92% of incident SN cases, with higher exposure levels contributing most in older survivors.
  • Higher genetic risk based on polygenic risk scores (PRSs) accounted for a notable proportion, ranging from 1-52% of SN cases.
  • Chemotherapy exposure accounted for 3-35% of SN cases, and lifestyle factors contributed negligibly to the risk of SNs.

Implications and Future Directions

  • The study highlights the crucial need to consider both treatment history and genetic factors in developing effective risk assessment and surveillance strategies for childhood cancer survivors.
  • Future research could investigate the long-term effects of radiotherapy and chemotherapy on SN risk and explore novel approaches to reduce SN incidence.
  • The study's findings emphasize the importance of individualized risk assessment and tailored surveillance strategies for childhood cancer survivors.
Read Full Article